Literature DB >> 19287096

Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis.

Steven D Crowley1, Matthew P Vasievich, Phillip Ruiz, Samantha K Gould, Kelly K Parsons, A Kathy Pazmino, Carie Facemire, Benny J Chen, Hyung-Suk Kim, Trinh T Tran, David S Pisetsky, Laura Barisoni, Minolfa C Prieto-Carrasquero, Marie Jeansson, Mary H Foster, Thomas M Coffman.   

Abstract

Studies in humans and animal models indicate a key contribution of angiotensin II to the pathogenesis of glomerular diseases. To examine the role of type 1 angiotensin (AT1) receptors in glomerular inflammation associated with autoimmune disease, we generated MRL-Faslpr/lpr (lpr) mice lacking the major murine type 1 angiotensin receptor (AT1A); lpr mice develop a generalized autoimmune disease with glomerulonephritis that resembles SLE. Surprisingly, AT1A deficiency was not protective against disease but instead substantially accelerated mortality, proteinuria, and kidney pathology. Increased disease severity was not a direct effect of immune cells, since transplantation of AT1A-deficient bone marrow did not affect survival. Moreover, autoimmune injury in extrarenal tissues, including skin, heart, and joints, was unaffected by AT1A deficiency. In murine systems, there is a second type 1 angiotensin receptor isoform, AT1B, and its expression is especially prominent in the renal glomerulus within podocytes. Further, expression of renin was enhanced in kidneys of AT1A-deficient lpr mice, and they showed evidence of exaggerated AT1B receptor activation, including substantially increased podocyte injury and expression of inflammatory mediators. Administration of losartan, which blocks all type 1 angiotensin receptors, reduced markers of kidney disease, including proteinuria, glomerular pathology, and cytokine mRNA expression. Since AT1A-deficient lpr mice had low blood pressure, these findings suggest that activation of type 1 angiotensin receptors in the glomerulus is sufficient to accelerate renal injury and inflammation in the absence of hypertension.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19287096      PMCID: PMC2662542          DOI: 10.1172/JCI34862

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  74 in total

1.  Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor.

Authors:  G Wolf; F N Ziyadeh; F Thaiss; J Tomaszewski; R J Caron; U Wenzel; G Zahner; U Helmchen; R A Stahl
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Roles of interferon-gamma and interleukin-4 in murine lupus.

Authors:  S L Peng; J Moslehi; J Craft
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

3.  IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice.

Authors:  C Haas; B Ryffel; M Le Hir
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

4.  Renal growth and development in mice lacking AT1A receptors for angiotensin II.

Authors:  M I Oliverio; K Madsen; C F Best; M Ito; N Maeda; O Smithies; T M Coffman
Journal:  Am J Physiol       Date:  1998-01

Review 5.  Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis.

Authors:  W A Border; N A Noble
Journal:  Hypertension       Date:  1998-01       Impact factor: 10.190

6.  Expression of type 1 angiotensin II receptor subtypes and angiotensin II-induced calcium mobilization along the rat nephron.

Authors:  N Bouby; A Hus-Citharel; J Marchetti; L Bankir; P Corvol; C Llorens-Cortes
Journal:  J Am Soc Nephrol       Date:  1997-11       Impact factor: 10.121

7.  Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice.

Authors:  D Balomenos; R Rumold; A N Theofilopoulos
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

8.  Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril.

Authors:  Y Furukawa; A Matsumori; T Hirozane; S Sasayama
Journal:  Circulation       Date:  1996-01-15       Impact factor: 29.690

9.  Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism.

Authors:  S C Amuchastegui; N Azzollini; M Mister; A Pezzotta; N Perico; G Remuzzi
Journal:  J Am Soc Nephrol       Date:  1998-10       Impact factor: 10.121

10.  Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice.

Authors:  S Takahashi; L Fossati; M Iwamoto; R Merino; R Motta; T Kobayakawa; S Izui
Journal:  J Clin Invest       Date:  1996-04-01       Impact factor: 14.808

View more
  47 in total

Review 1.  New insights into angiotensin receptor actions: from blood pressure to aging.

Authors:  Johannes Stegbauer; Thomas M Coffman
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-01       Impact factor: 2.894

2.  A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension.

Authors:  Jian-dong Zhang; Mehul B Patel; Young-Soo Song; Robert Griffiths; James Burchette; Phillip Ruiz; Matthew A Sparks; Ming Yan; David N Howell; Jose A Gomez; Robert F Spurney; Thomas M Coffman; Steven D Crowley
Journal:  Circ Res       Date:  2012-04-24       Impact factor: 17.367

Review 3.  Atherosclerotic renal artery stenosis: current status.

Authors:  Soon Hyo Kwon; Lilach O Lerman
Journal:  Adv Chronic Kidney Dis       Date:  2015-05       Impact factor: 3.620

Review 4.  Immunologic Effects of the Renin-Angiotensin System.

Authors:  Steven D Crowley; Nathan P Rudemiller
Journal:  J Am Soc Nephrol       Date:  2017-02-01       Impact factor: 10.121

5.  A maladaptive role for EP4 receptors in podocytes.

Authors:  Erin M Stitt-Cavanagh; Wissam H Faour; Kaede Takami; Anthony Carter; Barbara Vanderhyden; Youfei Guan; Andre Schneider; Matthew D Breyer; Christopher R J Kennedy
Journal:  J Am Soc Nephrol       Date:  2010-07-29       Impact factor: 10.121

6.  Calmodulin-dependent protein kinase II/cAMP response element-binding protein/Wnt/β-catenin signaling cascade regulates angiotensin II-induced podocyte injury and albuminuria.

Authors:  Lei Jiang; Lingling Xu; Yuxian Song; Jianzhong Li; Junhua Mao; Allan Zijian Zhao; Weichun He; Junwei Yang; Chunsun Dai
Journal:  J Biol Chem       Date:  2013-06-26       Impact factor: 5.157

7.  Angiotensin receptor blocker protection against podocyte-induced sclerosis is podocyte angiotensin II type 1 receptor-independent.

Authors:  Taiji Matsusaka; Takako Asano; Fumio Niimura; Masaru Kinomura; Akihiro Shimizu; Ayumi Shintani; Ira Pastan; Agnes B Fogo; Iekuni Ichikawa
Journal:  Hypertension       Date:  2010-02-08       Impact factor: 10.190

Review 8.  Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis.

Authors:  Gabriela Campanholle; Giovanni Ligresti; Sina A Gharib; Jeremy S Duffield
Journal:  Am J Physiol Cell Physiol       Date:  2013-01-16       Impact factor: 4.249

Review 9.  Lupus nephritis: lessons from murine models.

Authors:  Anne Davidson; Cynthia Aranow
Journal:  Nat Rev Rheumatol       Date:  2009-12-01       Impact factor: 20.543

10.  Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system.

Authors:  Johannes Stegbauer; De-Hyung Lee; Silvia Seubert; Gisa Ellrichmann; Arndt Manzel; Heda Kvakan; Dominik N Muller; Stefanie Gaupp; Lars Christian Rump; Ralf Gold; Ralf A Linker
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.